Pharming Group N.V. reported robust financial performance for the second quarter of 2025, with total revenues growing by 26% year-on-year to reach $93.2 million. This strong top-line growth contributed to a meaningful operating profit of $12.9 million, a significant turnaround from a loss in the previous year, excluding nonrecurring acquisition-related expenses.
RUCONEST continued its foundational role, achieving $80.4 million in Q2 2025, a 28% increase over Q2 2024, driven by new prescribers and patient enrollments. Joenja also showed accelerating patient uptake, with a 15% revenue increase to $12.8 million.
Reflecting this strong momentum, Pharming raised its full-year 2025 total revenue guidance to between $335 million and $350 million, up from the prior guidance of $325 million to $340 million. This implies a full-year revenue growth between 13% and 18%, driven by continued strong performance and anticipated catalysts for Joenja.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.